Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Approval granted for clinical trial application of nine-valent HPV vaccine in males.

Beijing Wantai Biological Pharmacy Enterprise (603392.SH) has issued an announcement that its wholly-owned subsidiary, Xiamen Wantai Ocean Biotechnology Co., Ltd., has received a "Drug Clinical Trial Notification" (Notification Number: 2024LP02590) issued by the National Medical Products Administration. The notification allows the company to conduct clinical trials for its nine-valent human papillomavirus vaccine (Escherichia coli) (referred to as "nine-valent HPV vaccine") targeting male populations.